

# Important Changes to Clozapine Access in Quebec



Viatriis empowers people worldwide to live healthier at every stage of life.

Dear Healthcare Professional,

Government of Quebec recently announced<sup>1</sup> that as of April 15th, 2021 drug manufacturers will no longer be allowed to pay or reimburse in part or in full the price of drugs to patients when a generic alternative is available. The new regulation does include some exceptions including a grandfather clause allowing patients already on treatment prior to April 15th, 2021 to continue benefiting from coupon cards for medication that has generic alternative.

- Gen-Clozapine is the generic alternative to Clozaril<sup>®†</sup> and the TOP selling generic antipsychotic medication in Canada<sup>2</sup>

For more information about Gen-Clozapine or GenCAN patient support and monitoring program please contact Lesley Hutcheson directly at (866) 657-4747.

<sup>1</sup> [GAZETTE OFFICIELLE DU QUÉBEC](#)

<sup>†</sup> CLOZARIL is the product of HLS Therapeutics Inc.

<sup>2</sup> IQVIA CDH CompuScript MAT Q1'2021.



[Learn More](#)

Consult the Product Monograph [www.mylan.ca](http://www.mylan.ca) for more information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing.

The Product Monograph is also available by calling Mylan Pharmaceuticals ULC at 1-844-596-9526 or the GenCAN Gen-Clozapine Access Network at 1-866-501-3338.

CLZ-2021-0044B – MA2021